References
- Pedersen L, Christensen JF, Hojman P. Effects of exercise on tumor physiology and metabolism. Cancer J 2015; 21:111-6; PMID:25815851; http://dx.doi.org/10.1097/PPO.0000000000000096
- McTiernan A. Mechanisms linking physical activity with cancer. Nat Rev Cancer 2008; 8:205-11; PMID:18235448; http://dx.doi.org/10.1038/nrc2325
- Pedersen L, Idorn M, Olofsson GH et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. Cell Metabolism 2016 Mar 8; 23(3):554-62; http://dx.doi.org/10.1016/j.cmet.2016.01.011.
- Bigley AB, Rezvani K, Chew C et al. Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Brain Behav. Immun. 2014; 39:160-71. doi: 10.1016/j.bbi.2013.10.030. Epub;%2013 Nov 5.:160–171; PMID:24200514; http://dx.doi.org/10.1016/j.bbi.2013.10.030
- Stojanovic A, Correia MP, Cerwenka A. Shaping of NK cell responses by the tumor microenvironment. Cancer Microenviron 2013; 6:135-46; PMID:23242671; http://dx.doi.org/10.1007/s12307-012-0125-8
- Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr. Opin.Immunol 2015; 33C:23-35; PMID:25621841; http://dx.doi.org/10.1016/j.coi.2015.01.006
- Spranger S, Koblish HK, Horton B et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2014; 2:1-14; PMID:24829758; http://dx.doi.org/10.1186/2051-1426-2-3
- Andersen R, Donia M, Ellebaek E et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL-2 regimen. Clin. Cancer Res. epub ahead of print. PMID:27006492
- Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.CCR-11-0116
- Sistigu A, Yamazaki T, Vacchelli E et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20:1301-9; PMID:25344738; http://dx.doi.org/10.1038/nm.3708